resTORbio, Inc. (TORC) financial statements (2021 and earlier)

Company profile

Business Address 500 BOYLSTON STREET
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:95927
Cash and cash equivalents84347
Short-term investments10  
Other undisclosed cash, cash equivalents, and short-term investments 58 
Receivables3  
Prepaid expense121
Other current assets000
Other undisclosed current assets1(0)101
Total current assets:10093110
Noncurrent Assets
Operating lease, right-of-use asset23 
Property, plant and equipment300
Intangible assets, net (including goodwill)20  
Goodwill20  
Restricted cash and investments500
Other noncurrent assets2  
Other undisclosed noncurrent assets1  
Total noncurrent assets:5310
TOTAL ASSETS:15494110
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6126
Accounts payable273
Accrued liabilities053
Employee-related liabilities4  
Deferred revenue14 
Other undisclosed current liabilities3  
Total current liabilities:22126
Noncurrent Liabilities
Long-term debt and lease obligation20  
Operating lease, liability20 
Liabilities, other than long-term debt000
Deferred income tax liabilities0 
Other liabilities 00
Other undisclosed noncurrent liabilities1  
Total noncurrent liabilities:2200
Total liabilities:44126
Stockholders' equity
Stockholders' equity attributable to parent11082104
Common stock000
Additional paid in capital216236176
Accumulated other comprehensive income (loss)00(0)
Accumulated deficit(106)(154)(71)
Total stockholders' equity:11082104
TOTAL LIABILITIES AND EQUITY:15494110

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:18  
Operating expenses(57)(85)(40)
Operating loss:(39)(85)(40)
Nonoperating income (expense)(1)32
Investment income, nonoperating 3 
Other nonoperating income (expense)(1)(0)2
Interest and debt expense(0)  
Loss from continuing operations before equity method investments, income taxes:(40)(83)(38)
Other undisclosed income from continuing operations before income taxes1  
Loss from continuing operations before income taxes:(39)(83)(38)
Income tax expense (benefit)3(0)(0)
Net loss available to common stockholders, diluted:(37)(83)(38)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(37)(83)(38)
Other comprehensive income0  
Comprehensive loss:(37)(83)(38)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 0(0)
Comprehensive loss, net of tax, attributable to parent:(37)(83)(38)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: